greeksoup/ stock research

Rxo (RXO) Q4 FY2024 earnings: revenue $1.7 billion, up 70.4% on the year

Rxo, Inc. (RXO) reported revenue of $1.7 billion for Q4 FY2024, the quarter ended 31 December 2024, up 70.4% on the same quarter a year earlier. Net income was -$25 million. The figures are the company's own, from the 10-K it filed with the SEC on 27 February 2025.

Revenue$1.7 billionup 70.4%
Net income-$25 million
Diluted EPSn/a
QuarterQ4 FY2024ended 31 December 2024

The quarter, against the one before and a year earlier

LineQ4 FY2024Q3 FY2024Q4 FY2023Change on the year
Revenue1,6671,040978+70.4%
Cost of revenue1,357809743+82.6%
Gross profit310231235+31.9%
Gross margin18.6%22.2%24.0%
Selling, general and administrative218149146+49.3%
Operating income-24.0-20.014.0n/a
Operating margin-1.4%-1.9%1.4%
Pre-tax income-33.0-2424.0n/a
Income tax-8.01.02.0n/a
Effective tax raten/an/a50.0%
Net income-25.0-2432.0n/a
Net margin-1.5%-23.4%0.2%
Diluted EPSn/a-$1.81$0.02n/a
$ million except per share.
Read moreFourth quarters are the year less the first three quarters. Free cash flow is operating cash flow less capital expenditure; the effective tax rate is income tax over pre-tax income; margins are the line over revenue. Gross profit is revenue less cost of revenue, and operating income is revenue less the company's own total costs, where the statement does not print those lines. Those four are arithmetic on the filed numbers; everything else is as filed. Money is in $ million as the company files it, or in $ billion by the switch above the tables; per share figures and share counts are as they are.

Cash flow and capital returned

LineQ4 FY2024Q3 FY2024Q4 FY2023Change on the year
Operating cash flow-7.0-7.019.0n/a
Capital expenditure12.011.018.0-33.3%
Free cash flow-19.0-18.01.0n/a
Free cash flow margin-1.1%-1.7%0.1%
Cash from investing-12.0-1,030-19.0n/a
Cash from financing1.01,085-100n/a
Depreciation and amortisation33.021.015.0+120.0%
Share-based compensation6.06.03.0+100.0%
Buybacksn/a0.0n/an/a
Diluted shares, weighted133m134m120m+11.6%
Shares outstanding at period end163m161m117m+38.9%

Cash flow lines for the quarter; where the company files them year to date, the quarter is the difference between two filings.

Balance sheet at quarter end

LineQ4 FY2024Q3 FY2024Q4 FY2023Change on the year
Shareholders' equity1,6121,652594+171.4%
Debt351352356-1.4%
Operating lease liabilities215261146+47.3%
Finance lease liabilities2.0n/a4.0-50.0%
Other liabilities1,2341,127725+70.2%
Total liabilities and equity3,4143,3921,825+87.1%
Fixed assets135175124+8.9%
Goodwill1,1231,027630+78.3%
Intangible assets49956568.0+633.8%
Cash and equivalents35.055.05.0+600.0%
Receivables1,2271,138743+65.1%
Other assets395432255+54.9%
Total assets3,4143,3921,825+87.1%

Questions

What was Rxo's revenue in Q4 FY2024?

Rxo (RXO) reported revenue of $1.7 billion for Q4 FY2024, the quarter ended 31 December 2024, up 70.4% on the same quarter a year earlier.

How much did Rxo earn in Q4 FY2024?

Net loss for Q4 FY2024 was $25 million.

When did Rxo report Q4 FY2024 results?

Rxo filed its 10-K for the year that ended with the quarter on 27 February 2025; the fourth quarter is the year less the first three.

Quarterly results, the last 12 quarters

Q3 FY2023Q4 FY2023 *Q1 FY2024Q2 FY2024Q3 FY2024Q4 FY2024 *Q1 FY2025Q2 FY2025Q3 FY2025Q4 FY2025 *Q1 FY2026Q2 FY2026
Revenue9769789139301,0401,6671,4331,4191,4211,4691,4251,774
Cost of revenue7427436997008091,3571,1531,1181,1371,2031,1711,472
Gross profit234235214230231310280301284266254302
Gross margin24%24%23%25%22%19%20%21%20%18%18%17%
SG&A148146145154149218210214208200197211
Operating income6.014.0-12.00.0-20.0-24.0-30.00.0-7.0-42.0-28.01.0
Operating margin1%1%-1%0%-2%-1%-2%0%-0%-3%-2%0%
Pre-tax income-3.04.0-21.0-8.0-242-33.0-39.0-10.0-15.0-51.0-49.0-8.0
Tax raten/a50%n/an/an/an/an/an/an/an/an/an/a
Net income-1.02.0-15.0-7.0-243-25.0-31.0-9.0-14.0-46.0-36.0-9.0
Net margin-0%0%-2%-1%-23%-1%-2%-1%-1%-3%-3%-1%
Diluted EPS-$0.01$0.02-$0.13-$0.06-$1.81n/a-$0.18-$0.05-$0.08-$0.27-$0.21-$0.05
Operating cash flow4.019.07.0-5.0-7.0-7.0-2.023.023.07.0-7.0-40.0
Capital expenditure18.018.011.011.011.012.015.014.014.016.017.012.0
Free cash flow-14.01.0-4.0-16.0-18.0-19.0-17.09.09.0-9.0-24.0-52.0
Buybacks0.0n/an/an/a0.0n/an/an/an/an/an/an/a
Shares outstanding117m117m118m118m161m163m164m164m164m164m165m165m
Filing10-Q10-K10-Q10-Q10-Q10-K10-Q10-Q10-Q10-K10-Q10-Q
Each quarter as filed, linked to its filing.
Read more* The fourth quarter is the full year less the first three quarters, because the company files the year and not the quarter on its own. A fourth quarter's EPS and diluted share count are from the company's results press release for that quarter, used where the release gives the same revenue and net income as the table. Money is in $ million as the company files it, or in $ billion by the switch above the tables; per share figures and the share count are as they are. Free cash flow is operating cash flow less capital expenditure; the effective tax rate is income tax over pre-tax income; margins are the line over revenue. Gross profit is revenue less cost of revenue, and operating income is revenue less the company's own total costs, where the statement does not print those lines. Cash flow lines filed year to date are the difference between two filings. Shares outstanding are at the period end where the balance sheet tags them, otherwise the count on the filing's cover page. A derived fourth-quarter EPS is left blank when a split in the year makes the arithmetic meaningless.

Source

10-K for the period ended 31 December 2024, filed 27 February 2025, accession 0001929561-25-000044: the filing on EDGAR. All of Rxo, Inc.'s filings: EDGAR company page.

The same record on your computer

GreekSoup is also a free program for your own computer. It reads these same filings for the names you follow, refreshed as they land, with no account. One pasted line installs it.

Install